An open-label, 52-week extension to a 24-week, Multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group evaluation of the efficacy, safety, and tolerability of the once-daily rivastigmine patch formulation in patients with probable Alzheimer's disease (MMSE 10-20)

Trial Profile

An open-label, 52-week extension to a 24-week, Multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group evaluation of the efficacy, safety, and tolerability of the once-daily rivastigmine patch formulation in patients with probable Alzheimer's disease (MMSE 10-20)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned number of patients changed from 500 to 637 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top